News & Updates

Show Multimedia Only

Lecanemab continues to delay progression in AD at 4 years

20 May 2026 by

The 48-month analysis of the global phase III Clarity AD study shows that lecanemab continues to deliver benefit and delay progression in early Alzheimer's disease (AD).

Lecanemab continues to delay progression in AD at 4 years

20 May 2026

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

20 May 2026

The oral small-molecule TLR7/8 inhibitor enpatoran has shown a dose-dependent effect on disease activity in patients with active skin manifestations of cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) in the phase II WILLOW trial.

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

20 May 2026

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

19 May 2026

In the treatment of patients with covert hepatic encephalopathy, use of rifaximin results in improved cognitive performance and decreased cirrhosis-related adverse events, as shown in an open-label study.

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

19 May 2026

Nipocalimab + SoC sustains disease control in patients with myasthenia gravis

19 May 2026 by

Adding nipocalimab to standard-of-care (SoC) demonstrates sustained disease control through week 120 in adult patients with antibody-positive generalized myasthenia gravis (gMG), including anti-AChR* or anti-MuSK**, according to the Vivacity-MG3 open-label extension (OLE) study presented at AAN 2026.

Nipocalimab + SoC sustains disease control in patients with myasthenia gravis

19 May 2026

Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer

18 May 2026 by

In the PREcoopERA window-of-opportunity trial, the selective estrogen receptor degrader (SERD) giredestrant shows robust anticancer activity, either alone or in combination with the luteinizing hormone-releasing hormone (LHRH) analogue triptorelin, in premenopausal women with ER+/HER2– operable invasive breast cancer.

Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer

18 May 2026

Digoxin may mitigate worsening of rheumatic heart disease

18 May 2026

Treatment with digoxin appears to reduce the risks of mortality and new-onset or worsening heart failure in patients with rheumatic heart disease (RHD), according to a study.

Digoxin may mitigate worsening of rheumatic heart disease

18 May 2026

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

17 May 2026 by

A top-down approach of initiating treatment with infliximab plus immunomodulator upon diagnosis of Crohn’s disease (CD) reduces the risk of related abdominal surgery, as well as those of disease progression and hospitalization, as compared with the conventional step-up approach, according to long-term data from the PROFILE trial.

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

17 May 2026

Folic acid supplementation may prevent adverse offspring outcomes in ASM-exposed pregnancies

16 May 2026

In pregnant women exposed to antiseizure medications (ASMs), supplementation with folic acid helps lower the risk of adverse offspring outcomes, according to a study.

Folic acid supplementation may prevent adverse offspring outcomes in ASM-exposed pregnancies

16 May 2026

GLP-1 RA prevents relapse, cuts weight in AUD patients with MetD

16 May 2026 by

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrates superiority over current FDA-approved pharmacotherapies for alcohol use disorder (AUD), reducing the risk of AUD after 1 year of therapy, reports a study presented at DDW 2026.

GLP-1 RA prevents relapse, cuts weight in AUD patients with MetD

16 May 2026

Vunakizumab beneficial in axial spondyloarthritis

16 May 2026

Treatment with vunakizumab appears to yield substantial improvements in signs and symptoms of radiographic axial spondyloarthritis (r-axSpA), as shown in a phase 2/3 trial.

Vunakizumab beneficial in axial spondyloarthritis

16 May 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Lecanemab continues to delay progression in AD at 4 years

Lecanemab continues to delay progression in AD at 4 years

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

Novel small-molecule TLR7/8 inhibitor shows therapeutic potential in lupus

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

Nipocalimab + SoC sustains disease control in patients with myasthenia gravis

Nipocalimab + SoC sustains disease control in patients with myasthenia gravis

Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer

Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer

Digoxin may mitigate worsening of rheumatic heart disease

Digoxin may mitigate worsening of rheumatic heart disease

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

Folic acid supplementation may prevent adverse offspring outcomes in ASM-exposed pregnancies

Folic acid supplementation may prevent adverse offspring outcomes in ASM-exposed pregnancies

GLP-1 RA prevents relapse, cuts weight in AUD patients with MetD

GLP-1 RA prevents relapse, cuts weight in AUD patients with MetD

Vunakizumab beneficial in axial spondyloarthritis

Vunakizumab beneficial in axial spondyloarthritis